Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software

Malvern, PA |  Jun 21, 2018

• New features bring high-level clinical capabilities to PET imaging in oncology and neurology

 

At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 at the Pennsylvania Convention Center in Philadelphia, Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo.via VB30 for Molecular Imaging (MI), the latest version of the company’s intelligent imaging software. syngo.via VB30 for MI has new features designed to bring advanced clinical capabilities to positron emission tomography/computed tomography (PET/CT) imaging in oncology and neurology. These capabilities can expand precision medicine and transform the delivery of patient care.

 

syngo.via VB30 for MI automatically calculates a patient’s Deauville score – an internationally recognized scoring system used by oncologists in the initial staging and evaluation of therapeutic response for patients with Hodgkin lymphoma and most types of non-Hodgkin lymphoma. By avoiding the laborious, time-consuming task of manual Deauville score determination, clinicians can save time and increase efficiency.

 

Also, syngo.via VB30 for MI offers a unique platform for viewing and interpreting parametric PET images. Using dedicated layouts that permit simultaneous visualization of the summed Standard Uptake Values (SUV), the metabolic rate of glucose (MRFDG), and distribution volume images, readers can easily quantify the FDG uptake of these parametric indices.
Additionally, the new platform’s PET/CT and SPECT/CT hybrid VRT (volume-rendering technique) feature enables 3D visualization of the disease state in a single image. This feature permits user-friendly interpretation of the cancer relative to anatomical landmarks.

 

Finally, syngo.via VB30 for MI offers improvements for the quantitative analysis of various neurological conditions via either self-created or widely used databases for various disease states. The assessment of striatal activity in the evaluation of Parkinson’s disease, hypometabolic seizure foci in the evaluation of epilepsy, and amyloid plaque burden in the evaluation of dementia can be conducted quantitatively. This ability provides more information to the reading physician to help increase diagnostic confidence.

 


Contact for journalists
Jeff Bell
Phone: (484) 868-8346; Email: jeffrey.t.bell@siemens-healthineers.com


Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services.
In fiscal 2017, which ended on September 30, 2017, Siemens Healthineers generated revenue of €13.8 billion and profit of €2.5 billion and has about 48,000 employees worldwide. Further information is available at www.siemens-healthineers.com.

 


Share this page: